Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 19NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

licogliflozin 1CKD732 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Obesity × Clear all
NCT03152591 2021-01-05

PCOS

Novartis

Phase 2 Completed
29 enrolled 24 charts
Other

Insulin Resistance, Obesity, Polycystic Ovary Syndrome, Hyperandrogenism, Overweight

NCT02063295 2016-07-18

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Zafgen, Inc.

Phase 2 Completed
14 enrolled
CNSOther

Craniopharyngioma, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡